Sygnature Discovery
JANUARY 17, 2023
About SB Drug Discovery SB Drug Discovery is an industry leader in specialist contract research, providing critical data for novel drug development through cell line generation, assay development and compound screening services. SB is based in Glasgow and employs 55 people.
PPD
OCTOBER 18, 2023
With the depth of knowledge to support all types of pharmaceutical products across all phases of development, we provide services ranging from end-to-end assay development to platform expansion, designed with the client’s timeline and budget in mind. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PerkinElmer
NOVEMBER 12, 2020
In drug development, assays are test systems that gauge the effects of chemical compounds on certain cellular, molecular, or biochemical processes. They are a vital step in modern pharma research that pushes drugs to market faster. These are just three of the steps to take toward reliable and replicable assay development.
The Pharma Data
SEPTEMBER 8, 2021
TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments. “We
Drug Target Review
OCTOBER 3, 2024
This comprehensive toolbox of Type 1, Type 2, Type 3 and Type 4 anti-idiotypic antibodies provides PK and ADA assay developers with enhanced flexibility for a thorough analysis of antibody candidates. Prior to this, he worked at an in vitro immuno-diagnostic company as Strategic Marketing Manager. Adapted from Harth S et al. (8)
The Pharma Data
JANUARY 27, 2021
These include in-vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. Cautionary Note Regarding Forward-Looking Statements.
Agency IQ
JULY 21, 2023
In May 2022, FDA responded to industry interest with a draft guidance on the use of ctDNA as a biomarker in investigational new drug (IND) and marketing applications for products intended to treat solid tumor malignancies in the early-stage setting. Read AgencyIQ’s analysis of the white paper and the meeting at which it was discussed here. ]
Expert insights. Personalized for you.
52 
Let's personalize your content